STRIDOX

This brand name is authorized in Nigeria.

Active ingredients

The drug STRIDOX contains one active pharmaceutical ingredient (API):

1	Doxycycline UNII 19XTS3T51U - DOXYCYCLINE HYCLATE
	Doxycycline is primarily bacteriostatic and is believed to exert its antimicrobial effect by the inhibition of protein synthesis.
	Read more about Doxycycline

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
A4-4957	Capsule	Stridox Capsules CAP 100 mg 10 x 10's	Capsule 131 RNW-PP-304049 STRIDOX CAPSULES DOXYCYCLINE CAPSULES 100MG Each Capsule contains Doxycycline Hyclate BP equ. to Doxycycline 100mg 115.414mg Maize Starch BP 95.701mg Lactose BP 11.00 mg Purified Talc BP 10.00 mg Colloidal Silicon Dioxide BP (Aerosil-200) 1.50 mg Sodium starch Glycolate BP 5.00mg Magnesium stearate BP 3.00mg Povidone k30 BP 3.00mg Isopropyl Alcohol BP 40.00mg Empty hard gelatin capsules size ‘2’Green cap/Green body –printed- Stridox on cap and Body BP/IN house 1.0 No. A4-4957 Drugs Nigerian Products 1010caps POM 1 12/12/2022 SAGAR VITACEUTICALS NIGERIA LTD., PLOT 2, LADIPO OLUWOLE STREET 9022977711 suptpharm@svnl.in Sagar Vitaceuticals Nigeria Limited, Plot 2, Ladipo Oluwole Street, Off Oba Akran Avenue, Ikeja, Lagos, Nigeria, Nigeria	21/12/2023

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J01AA02	Doxycycline	J Antiinfectives for systemic use → J01 Antibacterials for systemic use → J01A Tetracyclines → J01AA Tetracyclines
Discover more medicines within J01AA02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NG	Registered Drug Product Database	A4-4957